We are live on ! Find out more
EVOK

Evoke Pharma
EVOK

Delisted

EVOK was delisted on the 16th of December, 2025.

Back to rankings

14 hedge funds and large institutions have $3.06M invested in Evoke Pharma in 2016 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

56% more capital invested

Capital invested by funds: $1.97M → $3.06M (+$1.09M)

27% more funds holding

Funds holding: 11 → 14 (+3)

1.72% less ownership

Funds ownership: 5.33% → 3.61% (-1.7%)

Holders
14
Holders Change
+3
Holders Change %
+27.27%
% of All Funds
0.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
4
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SOMRS
State of Michigan Retirement System
Michigan
+$137K
2
Renaissance Technologies
Renaissance Technologies
New York
+$103K
3
BFA
BlackRock Fund Advisors
California
+$61.2K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$15.7K
5
UBS Group
UBS Group
Switzerland
+$13.3K

Top Sellers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
-$4.71K

EVOK Hedge Fund Activity: Q2 2016 in Review

14 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q2 2016, worth a combined $3.06M — up 56% from $1.97M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new EVOK positions and 0 closed out — a net gain of 3 holders — while 4 added to existing stakes and 1 trimmed.

The largest buyer was State of Michigan Retirement System, opening a new position worth an estimated $137K. The largest seller was Tower Research Capital (TRC), cutting an estimated $4.71K.

  • 14 institutional investors held Evoke Pharma (EVOK) as of Q2 2016, up from 11 in Q1 2016.
  • Funds reported $3.06M of Evoke Pharma stock for Q2 2016, up 56% quarter-over-quarter.
  • 3 funds opened new Evoke Pharma positions in Q2 2016 and 0 closed out, a net change of +3 holders.
  • The largest Evoke Pharma buyer in Q2 2016 was State of Michigan Retirement System, an estimated $137K added.
  • The largest Evoke Pharma seller in Q2 2016 was Tower Research Capital (TRC), an estimated $4.71K sold.

Based on aggregated 13F filings for Q2 2016.